# PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

Source: https://onco.cc/trials/nct06519266/  
OnCo record `nct06519266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Percutaneous hepatic perfusion in Uveal melanoma, run by Vastra Gotaland Region, now recruiting.

## Summary

PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases is a phase 3 interventional study registered as NCT06519266 by Vastra Gotaland Region, with 40 participants planned, started 2024-06-10 and due to reach its primary completion in 2028-12-31. Interventions recorded: PHP, IPI1/NIVO3, IPI3/NIVO1. Conditions recorded: Uveal Melanoma, Liver Metastases.

Linked to the technology Percutaneous hepatic perfusion because the registry's title names it ("percutaneous hepatic perfusion") and Uveal melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06519266
- Phase: 3
- Setting: A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination With Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients With Uveal Melanoma Liver Metastases
- Sponsor: Vastra Gotaland Region
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06519266: https://clinicaltrials.gov/study/NCT06519266

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [Percutaneous hepatic perfusion (chemosaturation)](https://onco.cc/technologies/percutaneous-hepatic-perfusion/)

---
JSON: https://onco.cc/api/v1/entities/nct06519266.json